Core Viewpoint - Shanghai Dongfulong Haiwei Biotechnology Co., Ltd. has obtained a patent for a "microfluidic technology-based nano-drug production device," indicating advancements in the field of specialized equipment manufacturing for pharmaceuticals [1] Company Overview - Shanghai Dongfulong Haiwei Biotechnology Co., Ltd. was established in 2016 and is located in Shanghai, focusing on the specialized equipment manufacturing industry [1] - The company has a registered capital of 50 million RMB [1] - According to Tianyancha data, the company has participated in 2 bidding projects and holds 66 patent records along with 4 trademark records and 5 administrative permits [1] Patent Details - The patent, authorized under announcement number CN223221374U, was applied for on July 2024 [1] - The device includes a first tank system, a second tank system, and a mixing system, designed to overcome existing deficiencies in nano-drug production [1] - The purpose of the device is to ensure thorough mixing of drugs, resulting in nano-drug products with precise size distribution and high encapsulation rates [1]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年3月4日， 芯易诊（CytoChip） 开发的 POCT血常规产品CitoCBC™ ，成为全球首款获得美国FDA 510(k)认证和CLIA豁免的卡片式 血常规。 即时血常规检测，提升诊疗体验 作为临床最常用的医学检验之一，血常规检测在美国市场需求旺盛，全美超过25万家CLIA豁免实验室可直接采用CitoCBC，在诊所、药店等 场景实现血常规检测，现场获取结果，大幅提升患者就诊体验。传统血常规设备难以满足CLIA豁免的"即插即用、免维护"要求，无法进入该 市场。 突破传统模式，打造全新诊所检测生态 长期以来，诊所血常规检测需外送至第三方实验室，年检测外送市场规模高达40亿美元。CitoCBC ® 凭借CLIA豁免优势，帮助诊所实现检测 能力、提升患者的诊断能力，同时保留检测收入。 在诊所常规检测项目中，大多数已有CLIA豁免产品，而血常规检测长期是唯一空白。CitoCBC ® 填补了这一关键缺口，成为诊所端完整 POCT检测体系的"最后一块拼图 ...